Phaseline

Companies › ProMis Neurosciences

ProMis Neurosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PMN310
Humanized IgG1 monoclonal antibody
–Phase 1Alzheimer Disease, Early OnsetDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06750432PMN310Phase 1Alzheimer Disease, Early OnsetNeurologyDec 2026

From the company's SEC filings

Cash and short-term investments of $53m on 2026-06-30; operating cash outflow about $46m a year; runway about 14 months at that burn, to Aug 2027

Press releases filed as 8-K in the last year:

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.